



The University of Utah

Pharmacotherapy Outcomes
Research Center

PORC

Pharmacotherapy Outcomes Research Center

University of Utah College of Pharmacy

MISSION STATEMENT

Our mission is to design and conduct outcomes research studies that assess the value of therapy in the treatment of disease and communicate their results. This is done in support of the academic mission of the University of Utah Health Sciences Center, which is to further education, research and service to improve patient care. Our center contracts with foundations, managed care organizations, government, and the pharmaceutical industry.

We are contracted to conduct research in the areas of patient reported outcomes, economic evaluations and education.

Pharmacotherapy Outcomes Research Center

421 Wakara Way, Suite 208

Salt Lake City, UT 84108

Phone: (801) 587-9639

Fax: (801) 587-7923

porc@pharm.utah.edu

www.pharmacy.utah.edu/PORC

FACULTY

Diana I. Brixner, RPh, PhD

Professor and Chair, Department of Pharmacotherapy
Executive Director Outcomes Research Center
University of Utah, College of Pharmacy

Diana I. Brixner, RPh, PhD, is currently Professor and Chair of the Department of *Pharmacotherapy* at the University of Utah College Of Pharmacy in Salt Lake City. She is also Executive Director of the Pharmacotherapy Outcomes Research Center, affiliated with the University of Utah Health Sciences Center, where she focuses on the design, conduct, training, and communication of pharmaco-economic and outcomes research studies to demonstrate the value of pharmaceutical therapy.



During her career, Dr. Brixner has published numerous articles in peer-reviewed journals, including the *Journal of National Cancer Center Networks*, *Value in Health*, *Pharmacoepidemiology and Drug Safety*, *the American Journal of Managed Care* and the *Journal of Managed Care Pharmacy*, authored 3 book chapters, has 1 issued patent, has been an invited speaker at a variety of professional meetings, and has presented numerous continuing education programs. She served a 2-year term on the Executive Board of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) and is the immediate past president of this association. She has served on the Health Outcomes Committee of the Pharmaceutical Research Manufacturers Association and is a long-standing member of the Academy of Managed Care Pharmacy (AMCP).

Gary Oderda, PharmD, MPH

Professor

Director Pharmacotherapy Outcomes Research Center

Dr. Oderda received his Pharm.D. degree from the University of California at San Francisco in 1972 and completed an Internship and Residency in Clinical Pharmacy at the University of California Hospital in 1973. Additional education was received at the Johns Hopkins University School of Hygiene and Public Health where he received a Masters in Public Health in 1982.

While at the University of Maryland College of Pharmacy, he served as Director of the Maryland Poison Center and as a faculty member. When he left in 1991 he was a Professor, Acting Assistant Dean and a Senior Policy Fellow at the Center for Drugs and Public Policy. After moving to the University of Utah he served as Professor and Chair of the Department of Pharmacy. He completed a sabbatical leave in 1999 in the Department of Health Care Management at Novartis Pharmaceuticals Corporation in East Hanover, New Jersey. He currently serves as a Professor and Director of the University of Utah Pharmacotherapy Outcomes Research Center.

Dr. Oderda has worked with Medicaid in a variety of capacities. He has managed contracts with Utah Medicaid for approximately 15 years. These contracts have included preparation of criteria sets for the Utah Medicaid DUR program, operation of the Drug Regimen Review Center (DRRC), and a Medicaid Transformation Grant. In addition, he has served as a consultant to Utah Medicaid and has done a number of studies using Medicaid data. At a national level, Dr. Oderda served as a member of a Technical Advisory Committee to CMS on quality measures in Medicare Part D. Dr. Oderda will assist in the interpretation of study results and assist in writing the final report/abstracts/manuscripts.



Joseph Biskupiak, PhD, MBA
Research Associate Professor
Director Pharmacotherapy Outcomes Research Center

Joseph E. Biskupiak, Ph. D., M.B.A., is a Research Associate Professor in the Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah. Dr. Biskupiak's research interests include health economics, disease management and the U.S. Healthcare system. Dr. Biskupiak is a member of the editorial board for *Pharmacy and Therapeutics*, a peer-reviewed journal for managed care and hospital formulary management.



Carl V. Asche, PhD
Research Associate Professor
Director of Graduate Studies

Dr. Asche is a Research Associate Professor and the Director of Graduate Studies in the Department of Pharmacotherapy at the University of Utah College of Pharmacy in Salt Lake City. Dr. Asche is also a member of the University of Utah Center on Aging and a managing partner of the Millcreek Outcomes Group, LLC. Dr. Asche received a Master of Science in Health Economics from the University of York and a Doctorate in Economics from the University of Surrey. Prior to joining the University of Utah, Dr. Asche spent 7 years in the pharmaceutical industry with Aventis Pharmaceuticals and the Bristol-Myers Squibb Pharmaceutical Group, where he managed health economics and outcomes research applied to both research and development (R&D) and customer marketing areas. Before entering the pharmaceutical industry, he worked as a Research Coordinator in the Department of Health Administration at the University of Toronto and as a Senior Economist for Alberta Health. Dr. Asche is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), International Health Economics Association (iHEA),



American Society of Health Economists, Canadian Association for Health Services and Policy Research, American Society of Health System Pharmacists, Academy of Managed Care Pharmacy (AMCP) and the Utah Gerontological Society. At a national and international level, Dr. Asche serves as co-chair of the ISPOR “Classification of Databases Working Group / Retrospective Database Special Interest Group”. He is a member of the standing scientific committee of the iHEA World Congress for 2007 (Copenhagen, Denmark) and 2009 (Beijing, China). Dr Asche is a member of the editorial boards of the AMCP Journal of Managed Care Pharmacy (JMCP), Journal of Antimicrobial Chemotherapy (JAC), and Current Medical Research and Opinion (CMRO). Dr. Asche is a reviewer for a number of journals including Diabetes Care, Pharmacoeconomics, American Public Health Association, CMRO, JAC, and JMCP. His research has included clinical and economic outcomes associated with infectious diseases, chronic obstructive pulmonary disease (COPD), asthma, Alzheimer’s disease, multiple sclerosis, diabetes, oncology, musculoskeletal disorders, urology, and women’s health. He has published widely, particularly in health services research and pharmacoeconomics.

Nancy Nickman, MS, PhD
Professor

Dr. Nancy Nickman is a Professor of Pharmacotherapy and Presidential Teaching Scholar in the College of Pharmacy at the University of Utah. She received a Bachelor of Science in Pharmacy degree from the University of Montana and graduate degrees from the University of Minnesota in both Hospital Pharmacy (M.S.) and Social and Administrative Pharmacy (Ph.D.). She also completed a two year ASHP Residency in Hospital Pharmacy at United and Children's Hospital in St. Paul, Minnesota (1982-1984). Nancy served as a tenured professor from 1987-2001, and returned to the faculty as a Professor of Pharmacotherapy in 2004 after owning her own business for five years. In 1995, she was



named a University of Utah Presidential Teaching Scholar (award merged in 1997 with the University of Utah Distinguished Teaching Award).

Her teaching and research interests include the human side of medication use and the medical care process. Research expertise includes patient-centered outcomes research to improve provision and quality of patient care based on application of industrial engineering and economic analyses. Publications and presentations include work sampling evaluations of institutional pharmacy services for re-design of structural and functional activities, pre-post analyses of the impact of technology on the practice of health professionals, simulated time-and-motion evaluations coupled with microcost analyses of issues related to medication preparation and administration, and simulated time-and motion analysis of devices intended for medication self-administration.

Nancy has received the University of Utah College of Pharmacy's Distinguished Teaching Award (1990), an Innovative Teaching Award from the American Association of Colleges of Pharmacy (1993), the Borchard Service-Learning Faculty Mentor Award (1994) from the Lowell Bennion Community Service Center at the University of Utah, and the Thomas Ehrlich Faculty Award for Service-Learning (1996) from Campus Compact. She also served as a Visiting Scholar in the Haas Center for Public Service at Stanford University (1996-1997), and received the Rufus J. Lyman Award from the *American Journal of Pharmaceutical Education* for the best manuscript published during 1998.

Joanne LaFleur, PharmD, MSPH
Research Assistant Professor

Dr. LaFleur is a research-track Assistant Professor at the University of Utah College of Pharmacy with the Pharmacotherapy Outcomes Research Center. She received her PharmD degree from the University of Utah College of Pharmacy in 2003 as well as a Masters of Science in Public Health from the Department of Family and Preventive Medicine in 2005. Joanne has a background in Drug Information and has completed a fellowship in



pharmacoeconomics and outcomes research. She has worked extensively with the Utah

Department of Health Medicaid drug program implementing a Drug Regimen Review Center, which continues to function under her oversight; the purpose of the program is to review patients with high drug utilization and provide interventions to prescribing clinicians aimed at improving drug therapy and decreasing costs. Joanne has publications in the areas of pharmacoeconomics, Medicaid drug utilization, hospital administration as it pertains to investigational drug services, and patient compliance with medication regimens.

Dr. LaFleur was Principal Investigator on a recent project in which adherence methods were evaluated using lipid-lowering therapy as a case example.⁶ She looked for correlations between several methods for calculating adherence ratios, including different methods for calculating the days of medication availability (numerator) and for determining the duration of the observation interval (denominator). She demonstrated that as many as one-third of patients were differently categorized as adherent or non-adherent depending on which method was selected. Dr. LaFleur also served as PI on a project to evaluate patient adherence to lipid-lowering therapy by regimen type.⁷ Patients on monotherapy versus one- or two-dosage-form combination therapy were categorized as adherent or non-adherent using a threshold of 80% and the odds of being adherent for patients receiving each regimen type was evaluated using logistic regression models. Patient-specific characteristics such as age, gender, patient out-of-pocket expenditures, and number of prescribed dyslipidemia agents, a surrogate for disease-severity, were also evaluated.

Michael Goodman, Ph.D.

Assistant Professor

Dr. Goodman is an Assistant Professor in the Department of Pharmacotherapy at the University of Utah College of Pharmacy. He received his doctorate from the University of Texas and Masters degree from the University of Oregon. Prior to joining the University of Utah, he spent time as a consultant with Xcenda, and as a



research investigator at HealthPartners and Kaiser Permanente. Dr. Goodman is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Society for Pharmacoepidemiology. His research interests include vaccine safety, drug safety, and the statistical analysis of rare events.

Carrie McAdam Marx, RPh, PhD

Research Assistant Professor

Carrie McAdam Marx, RPh, PhD, is a Research Assistant Professor at the University of Utah Pharmacotherapy Outcomes Research Center (PORC), where she participates in research studies that evaluate the value of pharmaceutical therapy. Prior to joining PORC, Dr. McAdam Marx spent 13 years in the pharmaceutical industry, most recently in the areas of strategic pricing and managed care sales and marketing. Previously she held roles focused on the development and delivery of disease management and appropriate use of medicines programs for private and public third party payers. Dr. McAdam-Marx research experience has been in the retrospective analysis of large pharmacy/medical claims and medical records databases with a current emphasis in the area of type 2 diabetes and hypertension. Dr. McAdam-Marx holds a PhD in Health Policy from the University of the Sciences in Philadelphia, a Masters' degree in Hospital Pharmacy from the University of Minnesota, and a Bachelor of Pharmacy degree from the University of Kansas.



Sameer Ghate, B.Pharm, MSPH

Research Associate, Adjunct Assistant Professor

Sameer Ghate is a Research Associate & Adjunct Assistant Professor at the Pharmacotherapy Outcomes Research Center (PORC) University of Utah. As a research associate his responsibility is to develop scientific research projects and act as a principal/co investigator, manage and train research staff to achieve research goals, collaborate with internal and external investigators and consultants on multiple research

projects ensuring significance and feasibility, summarize results of health outcome studies in the form of scientific abstracts and manuscripts and assist with grant preparation using knowledge of robust study design, methodology and statistical analysis. Prior to joining PORC, Sameer completed a two year health economics & outcomes research fellowship sponsored by TAP Pharmaceutical Products Inc., Lake Forest, IL in collaboration with University of Utah. During the first year as a research fellow at TAP he was involved with projects such as literature reviews, quality of life studies, health outcomes projects, budget impact modeling, retrospective claims database analysis, AMCP dossiers, and cost effectiveness studies. In the second year at PORC, Sameer managed and contributed to numerous projects involving retrospective database analysis using the GE/EMR database. During his graduate training at University of Louisville, Sameer was involved in lung cancer research projects such as quality of life studies, behavioral aspects of lung cancer screening and psychosocial outcomes in lung cancer outcomes research. He also had the opportunity to complete a 12-week internship in the Pharmacoeconomics and Outcome Research department at Humana Inc.

Sameer Ghate has a B.S. degree in Pharmacy from University of Pune, India and M.S. degree in Public Health from University of Louisville, KY. He is currently enrolled in the PhD program in Public Health at the Dept. of Family & Preventive Medicine, University of Utah, UT.

Sudhir Unni, PhD, MBA
Research Associate

Sudhir Unni is a Research Associate at the Pharmacotherapy Outcomes Research Center at the University of Utah. Prior to joining PORC, he spent two years in Xcenda (contract research organization) and was involved in various health economics and outcomes research projects for health care companies. Sudhir received his PhD in Pharmacy Administration and MBA in General Business from the University of Louisiana at Monroe and Bachelors in Pharmacy from the University of Pune, India. Prior to coming to the US, he worked as a product manager with an Indian pharmaceutical company for five years managing several brands.

ADJUNCT FACULTY

Vijay N. Joish, Ph.D.

Adjunct Research Faculty

Vijay N. Joish, is an adjunct research faculty at the University of Utah Pharmacotherapy Outcomes Research Center (PORC). His research interests are primarily in the area of pharmacoeconomics and pharmacopolitics and has extensive experience in designing and conducting retrospective claims database studies. He currently holds a full time position in the internal medicine health outcomes department at Sanofi Aventis where he manages health economic activities supporting marketed and pipeline CNS products. Dr. Joish got his doctoral degree from the University of Arizona in the area of pharmaceutical economics and policy. His dissertation work involved developing a diabetes specific risk-adjustment tool. He has a Master's in Pharmacy Administration from Idaho State University and a Bachelor's in Pharmaceutical Sciences from the University of Bombay.

Qayyim Said, Ph.D.

Adjunct Research Faculty

Dr. Said is an Assistant Professor at the Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences. He is also an Adjunct Assistant Professor at the Department of Pharmacotherapy, University of Utah. Prior to this, Dr. Said was a Research Assistant Professor at the Pharmacotherapy Outcomes Research Center (PORC), University of Utah. His research has focused on studying health and economic outcomes of health care interventions and investigating the impact of market and organizational characteristics on delivery of care. Dr. Said has extensive experience in using large administrative, electronic medical record and survey databases. While at PORC, he worked as a principal investigator or a co-investigator on projects funded by the University of Utah, Bristol-Myers Squibb, Pfizer, Sanofi-Aventis, and the Veterans Health Administration. Dr. Said is currently involved as a co-investigator in several projects at PORC.

Anke-Peggy Holtorf, Ph.D, MBA
Adjunct Research Faculty

Dr. Anke-Peggy Holtorf is adjunct faculty in the Department of Pharmacotherapy at the University of Utah College of Pharmacy. In the year 2006 to 2007 she was visiting assistant professor at the University of Utah. In addition to her academic contributions, she participates as investigator in a variety of studies conducted by the Pharmacotherapy Outcomes Research Center. Dr. Holtorf obtained her PhD (Dr. rer. nat.) from the University of Marburg (Germany) and her MBA from the University of Birmingham (United Kingdom). Dr. Holtorf is partner of BioBridge Strategies LLC (<http://www.bbstrategies.com>), an international consultancy firm helping pharmaceutical and diagnostic companies aligning their business strategies to the prospective value their products and services can contribute to the healthcare market. Dr. Holtorf looks back on 15 years of experience in the pharmaceutical and chemical industry in research, marketing with global responsibilities. Among others was responsible for the global Disease Management activities and strategy of Novartis Pharma, inc. Between 2000 and 2004, Dr. Holtorf managed the biotech business unit of a mid-sized Swiss chemical company and held a seat in the executive committee.

PORC FELLOWSHIPS

PORC provides a post-doctoral Fellowship in Outcomes Research and Pharmacoeconomics. The Fellowship is designed to provide training and experience at an academic outcomes research center to accomplish the following goals:

- To educate the fellow on outcomes research principles and applications, and their use in evaluating health care products and services;
- To provide experience in designing research studies which examine economic, clinical and humanistic outcomes; and
- To provide the training and experience necessary for the fellow to practice outcomes research in a pharmaceutical company, academic institution, managed care organization or healthcare facility.

Fellowships are generally two years and may include both years at PORC or a year at PORC and one additional year at a sponsoring institution, such as a pharmaceutical company or managed care company. Fellowship funding to date for joint programs has been obtained from Medco Health, Novartis Pharmaceuticals, and TAP Pharmaceuticals.

The majority of the Fellowship is spent working on outcomes research and pharmacoeconomics projects. The Fellow will be involved in all phases of the projects including proposal development, hypothesis generation, planning, data collection, data analysis, and generation of reports, presentations, and manuscripts. It is expected that the Fellow will present at least one abstract at a national meeting, such as AMCP, ASHP or ISPOR, and submit at least one manuscript for journal publication from work completed during the first year, and continue to make similar contributions in the second year.

Fellows are expected to participate in all areas of PORC research projects. In the beginning of the year they work under the direct supervision of faculty and second year Fellows. As they progress through the Fellowship they will be expected to demonstrate independence in the development of proposals, implementation of research, presentations and peer reviewed publications.

FELLOWS

Junhua Yu, Ph.D.

Research Fellow

Junhua Yu joined PORC as a first year fellow during the summer of 2008. During the first year as a research fellow at PORC, she was involved with projects such as retrospective claims database analysis and cost effectiveness studies. Junhua Yu received her Ph.D. in Health Economics from the University of Alabama. Her dissertation focused on the application of three nonlinear regression models in data for health care utilization using STATA and GAUSS. She also has an M.S. in applied statistics with concentration on Data Mining using SAS Enterprise Miner. Her modeling experience on Data Mining has focused on Decision Tree, Neural Network, and Logistic regression. As a Ph.D. student, she worked as a research and teaching assistant in the department of Economics, Finance, and Legal Studies at the University of Alabama. She has taught Principles of Microeconomics and Statistical Data Analysis at the University of Alabama.

Swetha Raparla, MS

Research Fellow

Swetha Raparla received her Master of Science degree in Pharmacy Administration from University of the Sciences in Philadelphia (USP). She had an opportunity to work as a Graduate Student Instructor for the department of Pharmacy Practice/Administration in USP. She also worked as a Research Associate in summer 2008 at Global Health Economics & Outcomes Research Inc., Summit, NJ. She has a Bachelor of Science (Honors) Degree in Pharmacy from Birla Institute of Technology and Science, India. Swetha joined PORC in summer 2009 to complete her first year of the fellowship sponsored by Novartis Pharmaceuticals Corporation.

Ming Yan, MS

Research Fellow

Ming Yan received his MS. in Pharmaceutical Socioeconomics from the University of Iowa in 2003. His master thesis focused on analyzing claim data from a PBM in Iowa to examine the effects of implementing a three-tier copayment pharmacy

benefit structure (\$5/\$10/\$25) on prescription drug utilization and costs, compared to a 20% coinsurance benefit structure. He also has a Bachelor's in Economics from Huazhong University of Science and Technology, China. His experience includes analyzing both prescription and medical data while working as a health care data analyst in Managed Care Organizations in US and China. Ming joined PORC in the summer of 2009 as a first year fellow and is involved with secondary data analysis and cost-effective studies.

Past Fellowship Recipients

Joanne LaFleur, PharmD, MSPH
Research Assistant Professor
University of Utah
Pharmacotherapy Outcomes Research Center
Salt Lake City, UT

Qayyim Said, Ph.D.
Assistant Professor
Division of Pharmaceutical Evaluation and Policy
University of Arkansas for Medical Sciences
Little Rock, AR

Mei-Jen Ho, PharmD, MSPH
Clinical Pharmacist
University of Utah
Drug Regimen Review Center
Salt Lake City, UT

Sameer R. Ghate, B.Pharm, MSPH
Research Associate
University of Utah
Pharmacotherapy Outcomes Research Center
Salt Lake City, UT

Vijay N. Joish, Ph.D.
Senior Manager, Health Outcomes
Sanofi Aventis
Bridgewater, NJ

Mark Roper
Clinical Pharmacist
University Hospital
Salt Lake City, UT

Jaewhan Kim, PhD
Assistant Professor
Division of Public Health
Department of Family & Preventive Medicine
University of Utah
Salt Lake City, UT

Richard E Nelson, PhD
Visiting Instructor
Division of Clinical Epidemiology
Department of Internal Medicine
University of Utah
Salt Lake City, UT

For more information on our Fellowship program, please visit our website at:
www.pharmacy.utah.edu/pharmacotherapy/fellowships/

MASTER OF SCIENCE IN PHARMACOTHERAPY

The Master of Science in Pharmacotherapy program is designed to provide students with training and education in the outcome evaluation of pharmacotherapy. Students interested in learning to effectively evaluate problems and issues in pharmacotherapy using evidence-based approaches to social and economic issues related to drug use in the community, institutional practice, managed care, long-term care or the pharmaceutical industry setting benefit from this advanced degree program. Faculty members in the Department of Pharmacotherapy have a wide variety of interests and extensive expertise in pharmacotherapy.

Outcomes Research Emphasis

The Pharmacotherapy Outcomes Research Center (PORC) is an affiliated program of the Department of Pharmacotherapy. The mission of PORC is to design, conduct, and communicate the results of outcomes research studies that demonstrate the value of pharmacotherapy in the treatment of disease. PORC faculty represent a group of full-time and affiliated investigators who use the Center's resources for outcomes research projects, and fellows who participate in the Center's approved projects in conjunction with their pursuit of advanced education.

For more information on our Master of Science program, please visit our website at:
www.pharmacy.utah.edu/pharmacotherapy/ms/programs.html

MASTER OF SCIENCE STUDENTS

Dusica Tasic, BS.Pharm, MSPA

Graduate Assistant

Dusica Tasic, born in Belgrade, Serbia, successfully completed her five year M.S. Diploma in Pharmacy from the University of Belgrade School of Pharmacy in 2006. During the summers of 2001 and 2004, her training in Belgrade included practicing in pharmacy. She commenced her Master of Science in Pharmacotherapy (Outcomes Research Emphasis) studies in the Fall of 2006 at the University of Utah College of Pharmacy, where she also works as a Graduate Assistant in the Pharmacotherapy Outcomes Research Center. Previously she was a member of the Association of Students of Pharmacy and currently is a member of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She has presented at ISPOR and currently serves as a manuscript reviewer for the Journal of Antimicrobial Chemotherapy (JAC).

Asha Krishnaraj, BS.Pharmacy, MSPA Candidate

Graduate Assistant

Asha Krishnaraj, born in Mumbai, India, successfully completed her four year B.S in Pharmaceutical Science from K M Kundnani College of Pharmacy, University of Mumbai in 2006. During the summer of 2005, her training in Mumbai included working experience Fredun Pharmaceutical Limited. During 2006-2007 she worked as pharmacist in a private clinic. She commenced her Master of Science in Pharmacotherapy (Pharmacy Practice Management Emphasis) studies in the Fall of 2007 at the University of Utah College of Pharmacy, where she also works as a Graduate Assistant in the Pharmacotherapy Outcome Research Center.

For more information on our Master of Science program, please visit our website at:

www.pharmacy.utah.edu/pharmacotherapy/ms/programs.html

New Graduate Students Fall 2009

Kuan-Ling Kuo, BS

Karina Raimundo, BS

Wejia Wang, BS

For more information on our Master of Science program, please visit our website at:

www.pharmacy.utah.edu/pharmacotherapy/ms/programs.html

STAFF

Brian Oberg, MBA

Programmer, Data Administrator

Brian Oberg is the programmer and data administrator for the Pharmacotherapy Outcomes Research Center. His background includes Bachelor degrees in Computer Science and Psychology. Prior to joining PORC, Brian worked for a large regional healthcare provider and has over a decade of experience in clinical programming and data mining.

Xiangyang Ye, MS

Senior Research Analyst

Xiangyang Ye is a Senior Research Analyst at the University of Utah College of Pharmacy Pharmacotherapy Outcomes Research Center (PORC). He holds a Masters degree in Statistics from Michigan State University. He is also a certified advanced SAS programmer. Prior to joining PORC, Xiangyang was a research analyst with the Department of Epidemiology at MSU, where he conducted survival data analysis using SAS and R. Previously, Xiangyang was an engineer and director of the Computer Center in a newspaper publishing company in China, responsible for data management and network design.

Holly Abel, BMus

Administrative Assistant

Holly Abel is the Administrative Assistant to Diana Brixner, and the Pharmacotherapy Outcomes Research Center. Her responsibilities include scheduling of meetings, correspondence, travel planning, and manuscript submission. She coordinates directly with the Research Project Coordinator and Accounting Specialist. Holly's diverse background includes a Bachelor Degree in Music with an emphasis in Vocal Performance from the University of Utah School of Music. She performs regularly with local symphony and opera companies, and as a member of The Mormon Tabernacle Choir.

Blaine Osborne
Research Project Coordinator

Blaine is the Research Project Coordinator for the Pharmacotherapy Outcomes Research Center. He prepares required documents for the Office of Sponsored Projects (OSP) on behalf of the Center for research projects. His other duties include monitoring proposals, grants, budgets, contracts, invoices and independent research agreements. He also assists the research faculty with document preparation and special projects. Blaine has worked in various public and private agencies in the Salt Lake Area and enjoys bringing his talents to the area of pharmacotherapy research.

Ha Phan, B.A.
Accounting Specialist

Ha Phan is responsible for Project Accounting for the Pharmacotherapy Outcome Research Center (PORC) and Drug Regimen Review Center (DRRC). She also monitors project expenditures including payroll distribution. Ha received a Bachelor degree from California State University in Business Administration. She has over ten year's experience in accounting, and administration with private and public industries.

PORC

Pharmacotherapy Outcomes Research Center

University of Utah College of Pharmacy

Publications, Abstracts and Presentations

As of March 2008 the Pharmacotherapy Outcomes Research Center has generated over 115 abstracts, 82 peer reviewed publications and 54 presentations that have been presented nationally and internationally including in Europe, Latin American and Asia Pacific countries.

JOURNAL PUBLICATIONS

2009 Published

1. **Brixner DI, McAdam-Marx C, Ye X, Boye KS, Nielsen LL, Wintle M, Misurski D, Fabunmi R.** (2009) Six-Month A1C, Weight and Cardiovascular Outcomes in Patients with Type 2 Diabetes Treated with Exenatide in an Ambulatory Care Setting. *Diabetes, Obesity and Metabolism*. (In Press)
2. **LaFleur J, Larsen B, Madden C, Gunning K, Stoddard GJ, Oderda L, Steinvort C, Oderda G.** Agreement between pharmacists for problem-identification: An initial quality measurement of cognitive services. *Annals of Pharmacotherapy*. 2009; In Press.
3. **Yu J, Brixner DI, Ghate SR, Gondor K.** A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. *Utah's Health: An Annual Review IX*. 2009
4. **McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH.** (2009) Prevalence and Characteristics of Patients with Resistant Hypertension in an Ambulatory Care Setting. *Clinical Therapeutics*. (In Press)

2008 Published

1. **Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.** (2008) Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs Aging.* 2008;25(7):611-22.
2. **Kirkness CS, Yu J, Asche CV.** The Effect on Comorbidity and Pain in Patients with Osteoarthritis. *J Pain Palliat Care Pharmacother.* 2008; 22(4) 336 - 48
3. **Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A.** (2008) Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. *Curr Med Res Opin.* Sep;24(9):2597-607
4. **Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.** (2008) Association between oral antidiabetic use, adverse events and outcomes in patients with type 2 diabetes. *Diabetes Obes Metab.* 2008 Aug;10(8):638-45. Epub 2007 Jul 21
5. **Kirkness CS, Marcus RL, Lastayo PC, Asche CV, Fritz JM.** (2008) Diabetes and associated risk factors in patients referred for physical therapy in a national primary care electronic medical record database. *Phys Ther.* 2008 Nov;88(11):1408-16. Epub 2008 Sep 18
6. **McAdam-Marx C, Schaaf D, Holtorf AP, Eng B, Oderda G.** (2008) Systematic Analysis of Outcomes Evaluations Applied to Drug Management Programs. *American Journal of Managed Care, Suppl.* Nov;14(11 Suppl):SP36-45
7. **Asche CV, Nelson RE.** The benefits and risks of new therapies for type 2 diabetes. *J Manag Care Pharm.* 2008 Sep;14(7):655-7. Review
8. **Asche CV, McAdam-Marx C, Seal B, Crookston B, Mullins CD.** (2008) Treatment Costs Associated with Community-Acquired Pneumonia by Community Level of Antimicrobial Resistance. *Journal of Antimicrobial Chemotherapy (JAC).* May; 61(5):1162-8. Epub 2008 Feb 29
9. **Asche C, Said Q, Joish V, Hall CO, Brixner DI.** (2008). Assessment of COPD-related outcomes via a national electronic medical record database. *International Journal of COPD,* 3(2): 323-6
10. **Asche C, McAdam-Marx C, Shane-McWhorter L, Plauschinat C.** (2008) Adverse Events and Oral Antidiabetic Outcomes Among Seniors in a Real World Setting. *Drugs and Aging.* 25(7):611-622
11. **Brixner DI, McAdam-Marx C.** (2008) Cost-Effectiveness of Insulin Analogs. *The American Journal of Managed Care.* Nov; 14(11): 766-75
12. **Brixner DI, Ghate SR, McAdam-Marx C, Ben-Joseph R, Said Q.** (2008). Association between cardiometabolic risk factors and body mass index on diagnosis and treatment codes in an electronic medical record database. *J Manag Care Pharm,* Oct; 14(8): 756-67 (Nominated as 1 of 15 articles by JMCP Editorial Advisory Board for 2008 JMCP Award of Excellence)

13. Jackson KC 2nd, Sheng X, **Nelson RE**, Keskinaslan A, **Brixner DI**. (2008) Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. *Clin Ther*. Aug;30(8):1558-63.
14. Hendlish SK, Horowicz-Mehler NC, **Brixner DI**, Stern LS, Doyle JJ, Chang J, Hagan M. (2008) Contraceptive and noncontraceptive benefits of the LNG-IUS in a vertically integrated HMO. *Contraception*. 2008 Jul;78(1):36-41. Epub 2008 May 14
15. **LaFleur J, McAdam-Marx C, Kirkness C, Brixner DI**. (2008). Clinical risk factors for fracture in post-menopausal osteoporotic women: a review of the recent literature. *Ann Pharmacother*, 42(3): 375-86. Epub 2008 Jan 29. Review.
16. Murphy PA, **Brixner DI**. (2008). Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database. *Contraception*, Apr; 77(4):257-63
17. **Holtorf AP**, Watkins JB, Mullins CD, **Brixner DI**. Incorporating observational data into the formulary decision-making process--summary of a roundtable discussion. *Journal of Managed Care Pharmacy: JMCP*, 2008, 14(3), 302-8
18. **Said Q**, Gutterman EM, Kim MS, Firth SD, Whitehead R, **Brixner DI**. Somnolence effects of antipsychotic medications and the risk of unintentional injury. *Pharmacoepidemiol Drug Saf*. 2008 Mar 4 [Epub ahead of print]
19. Kane SV, **Brixner DI**, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. *J Manag Care Pharm*. 2008 Jan;14(1 Suppl A):s2-12; quiz s13-5.
20. Merrill RM, Layman AP, **Oderda G, Asche CV**. Risk Estimates of Hysterectomy and Selected Conditions Commonly Treated with Hysterectomy. *Annals of Epidemiology*, 2008 Mar; 18(3): 253-60.
21. Muszbek N, **Brixner DI**, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. *Int J Clin Pract*. 2008 Feb;62(2):338-51

2007 Published

1. **Asche CV**. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: Results of a small survey of managed care organizations and pharmaceutical manufacturers. Commentary on the article by Nichols MB et al. *J Manag Care Pharm*. 2007 May;13(4):360-71
2. **Oderda GM, Said Q**, Evans RS, Stoddard GJ, Lloyd J, **Jackson K**, Rublee D, Samore MH. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. *Ann Pharmacother*. 2007 Mar;41(3):400-6. Epub 2007 Mar 6
3. **LaFleur J, Said Q, McAdam-Marx C, Jackson K**, Mortazavi M. The problems of studying the association between race and pain in outcomes research. *J Pain Palliat Care Pharmacother*. 2007;21(3):57-62
4. **Asche CV, Kirkness C, McAdam-Marx C**, Fritz J. The societal costs of low back pain A Review of Studies Published Between 2001 and 2007. *J Pain Palliat Care Pharmacother*. 2007;21(4):25-33.

5. **Nickman NA, Biskupiak J**, Creekmore F, Shah H, **Brixner DI**. Antiplatelet medication management in patients hospitalized with ischemic stroke. *Am J Health Syst Pharm*. 2007 Nov 1;64(21):2250-6.
6. **Brixner DI**, Rubin DT, Sewitch MJ. The Complexity of Compliance and Persistence in Ulcerative Colitis. *Gastroenterology and Hepatology*. 3(Suppl. 9) S1-10
7. **Asche C, Kirkness C, McAdam-Marx C**, Fritz J. The societal costs of low back pain: A Review of Studies Published Between 2001 and 2007. *Journal of Pain and Palliative Care Pharmacotherapy*, 2007, December, 21 (4).
8. **Asche C, McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat C. Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting. *Diabetes Obes Metab*. 2007 Jul 21
9. **Brixner DI**. Prevalence and burden of migraine and the impact on managed care. *Manag Care*. 2007 Jul;16(7 Suppl 7):2-3; discussion 15-7
10. **Brixner DI**. Prevalence and burden of migraine and the impact on managed care. *Currents: Pain Management News and Research*, E-Newsletter of the American Academy of Pain Management Nov. 2007
11. **Nickman NA, Biskupiak J**, Creekmore F, Shah H, **Brixner DI**. Antiplatelet medication management in patients hospitalized with ischemic stroke. *Am J Health Syst Pharm*. 2007; Nov 64(21):2250-6.
12. **Brixner DI**, Lenhart G, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion*. 2007; Nov 23(11):2887-95.
13. **McAdam-Marx C, LaFleur, J, Kirkness C, Asche CV**. Postmenopausal osteoporosis: current and future treatment options. *P&T*, 2007; 32(7):392-402
14. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat C. Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting. *Diabetes, Obesity and Metabolism*, 2007; Jul 21 [Epub ahead of print]
15. **Oderda G, Asche CV**, Jones K, Merrill R, Spalding J. Characterization of Therapy and Costs for Patients with Uterine Fibroids in Utah Medicaid. *Archives of Gynecology and Obstetrics*, 2007; 276(3):211-8. Epub Mar 7.
16. Brooks T, Creekmore F, Young D, **Asche CV, Oberg B**, Samuelson W. Hospitalization and Emergency Room Visit Rates in Asthma and Chronic Pulmonary Disease Patients Taking Beta-Blockers. *Pharmacotherapy*, 2007; 27(5):684-690
17. Wick J, **LaFleur J**. Fatigue: Implications in the elderly. *The Consultant Pharmacist*. 2007; 22(7):566-78
18. **Holtorf AP, LaFleur J**, Servatius D, Jeffries B, McBeth C, **Brixner DI**. Statin treatment of diabetic patients in Utah Medicaid. *Utah's Health: An Annual Review*, 2007; 12(Supplement):57-71
19. **Holtorf AP, LaFleur J**, Servatius D, Jeffries B, **Brixner DI**. Prescription drug use by women and men in Utah Medicaid. *Utah's Health: An Annual Review*, 2007; 12(Supplement):97-99
20. Tuteja AK, **Biskupiak JE**. Chronic Constipation: Overview and Treatment Options. *P&T*, 2007; 32(2):91-105

21. **Brixner DI, Joish V, Oderda GM**, Avey S, Hanson D, Cannon HE. Effects of Benefit Change Across 5 Disease States. *The American Journal of Managed Care*, 2007; 13(6 pt 2):370-6
22. **Jackson K**, Nahoopii R, **Said Q**, Dirani R, **Brixner DI**. An Employer-Based Cost Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation. *Journal of Occupational and Environmental Medicine*, 2007; 49(4): 453-60
23. Ho MJ, Kirkness C, **Brixner DI** (2007) Problem Based Learning in Pharmacy Management. *Journal of Pharmacy Teaching*, 49(4), 453-60.
24. **Brixner DI, Said Q, Kirkness C, Oberg B**, Ben-Joseph R, **Oderda G**. Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database. *Value Health*, 2007; 10(Suppl 1):S29-36
25. **Brixner DI**, Miller P, Fox J, Calabrese D, Tangalos E, Gruber J, Skinner N. The Role of Observational Data in Clinical Decision-Making for Osteoporosis: Commentaries from Managed Care and Senior Care [C.E. Program]. *Hotwire for Managed Markets*, April 2007

2006 Published

1. **Asche CV**, Seal B, **Jackson K, Oderda GM**. Economic evaluations in pain management: Principles and Methods. *Journal of Pain and Palliative Care Pharmacotherapy*, 2006; 20(3)
2. Maio V, Yuen EJ, Smith KD, **Brixner DI, Oderda GM, Asche CV**, Morgan S. Multi-national assessment of outcomes via retrospective database. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Connections*, 2006; 12(4)
3. **Jackson KC**. Pharmacotherapy for neuropathic pain. *Pain Pract.* 2006 Mar;6(1):27-33. Review.
4. **Brixner DI**. The case against excessive cost sharing. *American Journal of Managed Care*, 2006; 12(6 Suppl):S162-4.
5. **Brixner DI, Oderda GM, Nickman NA**, Beveridge R, Vermulen L, Jorgenson J. Documentation of chemotherapy infusion preparation costs in academic and community-based oncology practices. *Journal of the National Comprehensive Cancer Network*, 2006; 4(3):197-208
6. **Brixner DI, Oderda GM**, Roland CL, Rublee DA. Opioid expenditures and utilization in the Medicaid system. *Journal of Pain and Palliative Care Pharmacotherapy*, 2006; 20(1):5-13.
7. **Brixner DI, Said Q**, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, **Oderda GM**. Naturalistic impact of second-generation antipsychotics on weight gain. *The Annals of Pharmacotherapy*, 2006; 40(4):626-32. Epub 2006Mar 28.
8. **LaFleur J**, McBeth C, Gunning K, Oderda L, Steinvooort C, **Oderda GM**. A Pharmacist-Run Drug Regimen Review Center: Prevalence of Drug-Related Problems among Medicaid High Utilizers. *Journal of Managed-Care Pharmacy*; 2006; 12(8):677-85

9. **LaFleur J**, Thompson C, **Joish VN**, Charland SL, **Oderda GM**, **Brixner DI**. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. *Annals of Pharmacotherapy*, 2006; 40(7-8):1274-9.
10. Sbarbaro J, Nicolau D, **Asche CV**. Management of community-acquired respiratory tract infections in an era of increasing antibiotic resistance. *Pharmacy and Therapeutics*, 2006; 31(5):106-111
11. **Biskupiak JE**, **Brixner DI**, Howard K, **Oderda GM**. Gastrointestinal complications of over-the-counter nonsteroidal anti-inflammatory drugs. *J Pain Palliat Care Pharmacother*, 2006; 20(3):7-14
12. **Joish VN**, Brady E, Stockdale WA, **Brixner DI**, Dirani R. Evaluating diagnosis and treatment patterns of COPD in primary care. *Treatments in Respiratory Medicine*, 2006; 5(4):283-93
13. Creekmore FM, **Oderda GM**, Pendleton RC, **Brixner DI**. Incidence and Economic Implications of Heparin-Induced Thrombocytopenia in Medical Patients Receiving Prophylaxis for Venous Thromboembolism. *Pharmacotherapy*, 2006; 26(10):1438-45
14. **Brixner DI**. Assessment of the prevalence and costs of osteoporosis treatment options in a real-world setting. *Am J Managed Care*, 2006; 12(Suppl 7):S191-8; Erratum in *Am J Manag Care*, 2006; 12(7):370

2005 Published

1. **Asche CV**. Outcomes and economics in pain and palliative care Explicit mention of outcomes in prescribing information. *Journal of Pain and Palliative Care Pharmacotherapy*, 2005; 19(2):45-47
2. **Asche CV**, **Oderda G**, **Brixner D**. Has the cost-effectiveness of Xolair® (omalizumab) been underestimated? *The Journal of Allergy and Clinical Immunology*, 2005; 15(5):1095. Author reply 1095-6.
3. **Biskupiak, JE**, Korner E. Assessing the value of hospice care: Is documentation of cost savings necessary? *Journal of Pain and Palliative Care Pharmacotherapy*, 2005; 19(4):61-5
4. **Brixner DI**. Improving acute otitis media outcomes through proper antibiotic use and adherence. *The American Journal of Managed Care*, 2005; 11(6Suppl):S201-10.
5. **Brixner DI**. Managing the continuum of treatment: modeling the economic impact of treating Diabetes. *Journal of Managed Care Pharmacy*, 2005; 11(6, S-b):S19-S22.
6. **Brixner DI**, **Ho MJ**. Clinical, humanistic, and economic outcomes of gout. *American Journal of Managed Care*, 2005; 11(15Suppl):S459-64
7. Gerbino PP, **Brixner DI**, Sbarbaro J, Nicolau D. Appropriate antibiotic therapy for community-acquired respiratory tract infections. *Managed Care Interface*, 2005; 18(12):41-8

8. Halpern MT, Schmier JK, Snyder LM, **Asche CV**, Sarocco P, Nieman R, Lavin B, Mandell L. Meta-analysis of anti-microbial failure. *Journal of Antimicrobial Chemotherapy*, 2005; 55(5):748-57
9. **Ho MJ, Joish VN, Biskupiak J**. The role of pharmacoeconomics in formulary management: Triptan Case Study for Migraine. *Pharmacy and Therapeutics*, 2005; 30(1):36-46
10. **Joish VN, Oderda GM**. Understanding cost-utility analysis and its application. *Journal of Pain and Palliative Care Pharmacotherapy*, 2005; 19(1):57-61
11. **Joish VN**, Malone DC, Wendel C, Draugalis JR, Mohler MJ. Development and validation of a diabetes severity index (DSI) LA risk adjustment tool for predicting healthcare resource use and costs. *Pharmacotherapy*, 2005; 25(5):676-84
12. **Joish VN**, Donaldson G, Stockdale WA, **Oderda GM**, Crawley J, Sasane R, Joshua-Gotlib S, **Brixner DI**. Economic impact of GERD and PUD: examination of direct and indirect costs due to worker absenteeism using a large integrated patient database. *Current Medical Research and Opinion*, 2005; 21(4):535-44
13. **LaFleur J**. Evaluating the Relationship between treatment and costs-Measuring the atom with a yard-stick? *Journal of Managed Care Pharmacy*, 2005; 11(7):588-589
14. **LaFleur J**, Thompson C, Ho M, Stockdale W, Charland SL, **Oderda G**, **Brixner DI**. Cost analysis of combination vs. single dosage lipid lowering. *Hospital Formulary*, 2005; 40(7):233-234
15. McWhorter L, **Oderda GM**. Providing diabetes education and care to underserved patients in a collaborative practice at the Utah community health center. *Pharmacotherapy*, 2005; 25(1):96-109
16. Sullivan PW, Valuck R, **Brixner DI**, Armstrong EP. A pharmacoeconomic model for making value-based decisions about serotonin reuptake inhibitors. *Pharmacy and Therapeutics*, 2005; 30(2):96-106
17. Trost LF III, Wender RC, Suter CC, Rosenberg JH, **Brixner DI**, Von Worley AM, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Diagnosis guidelines. *Postgraduate Medicine*, 2005; 118(6):22-6
18. Trost LF III, Wender RC, Suter CC, Von Worley AM, **Brixner DI**, Rosenberg JH, Gunter MJ. National Epilepsy Panel. Management of epilepsy in adults. Treatment guidelines. *Postgraduate Medicine*, 2005; 118(6):29-33

2004 Published

1. Brandes JL, **Brixner DI**. Migraine Matters: The role of triptans in relieving the burden in management care. *Journal of Managed Care Pharmacy*, 2004; 10(4, S-b):S2-12

2. Briggs DD, **Brixner DI**, Cannon HE, George DL. Overview of chronic obstructive pulmonary disease: new approaches to patient management in managed care systems. *Journal of Managed Care Pharmacy*, 2004; 10(4, S-a):S2-10.
3. **Brixner DI**. Clinical and economic outcomes in the treatment of lower respiratory tract infections. *The American Journal of Managed Care*, 2004; 10(12):S400-407
4. **Brixner DI**. Standardizing managed care formulary submissions: the AMCP format. *Managed Care*, 2004; 13(5):14-17
5. Gunter MJ, Worley AV, Carter S, Gregory C, **Brixner DI**. Impact of a seizure disorder disease management program on patient-reported quality of life. *Disease Management Journal*, 2004; 7(4):333-347
6. **Ho MJ, Biskupiak J**. Would Depression Management Relieve Pain and Improve Function? *Journal of Pain and Palliative Care Pharmacotherapy*, 2004; 18(4):81-87
7. **Ho MJ, Joish VN, LaFleur J, Christensen RL, Brixner DI**. Pharmacoeconomic Analysis of Oral Triptans. *Formulary*, 2004; 39:356-357
8. **Ho MJ, LaFleur J**. The Treatment Outcomes of Pain Survey (TOPS): A Clinical Monitoring and Outcomes Instrument for Chronic Pain Practice and Research. *Journal of Pain Palliative Care Pharmacotherapy*, 2004; 18(2):49-59
9. **Joish VN, Brixner DI**. Back pain and productivity: measuring worker productivity from an employer's perspective. *Journal of Pain and Palliative Care Pharmacotherapy*, 2004; 18(2):79-85
10. **Joish VN, Malone DC, Wendel C, Mohler MJ**. Profiling quality of diabetes care in a Veterans Affairs healthcare system. *American Journal of Medical Quality*, 2004; 19(3):112-120
11. Kane S, Borisov NN, **Brixner DI**. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. *The American Journal of Managed Care*, 2004; 10(7):S216-226.
12. **LaFleur J, Oderda G**. Methods to measure Patient Compliance with Medication Regimens. *Journal of Pain and Palliative Care Pharmacotherapy*, 2004; 18(3):81-7
13. **Oderda GM, Osterhaus JT**. Outcomes and Economics in Pain Management, In Lipman A. (Ed.) Pain Management for Primary Care Clinicians, *American Society Health Systems Pharmacists*, 2004; 61:1490-3
14. Young D, Bleyl K, Clark T, **Oderda G, Liou T**. Increasing pneumococcal vaccination rates among adult patients with cystic fibrosis. *American Journal of Health Systems Pharmacists*, 2004; 61:1490-3.

2003 Published

1. Epple C, Wright AL, **Joish VN**, Bauer M. The role of the active family nutritional support in Type II diabetes metabolic control. *Diabetes Care*, 2003; 26(10):2829-34
2. **Joish VN**, Sahai A. Evaluating the role of confounding in pharmacoeconomic studies. *Managed Care Interface*, 2003; 16(12):L 30-35
3. **Joish VN**, Malone DC, Miller JM. A cost benefit analysis of vision screening methods for preschoolers and school-aged children. *Journal of American Association of Pediatric Ophthalmology & Strabismus*, 2003; 7(4):283-290; (2004) Letter to the Editor & Reply, *JAAPOS*. 8:74-75
4. **Oderda GM**. Cost-of-Illness Studies. *Journal of Pain and Palliative Care Pharmacotherapy*, 2003; 17(1):59-62
5. **Oderda G.M.**, Evans R.S., Lloyd J., Lipman A., Chen C., Ashburn M., Burke J., Samore M. Cost of Opioid Related Adverse Drug Events in Surgical Patients. *Journal of Pain and Symptom Management*, 2003; 25(3):276-83

2002 Published

1. **Oderda G.M.** Outcomes Research and Pharmacoeconomics – What it is and what it isn't. *Journal of Pain Palliative Care Pharmacotherapy*, 2002; 16(3):83-91
2. **Oderda G.M.** The Importance of Perspective in Pharmacoeconomic Analyses. *Journal of Pain Palliative Care Pharmacotherapy*, 2002; 16(4):65-69
3. Vermeulen LC, Windisch PA, Rydman RJ, Bruskiewitz RH, **Brixner DI**, Vlasses PH. Using a Multihospital Systems Framework to Evaluate and Establish Drug use Policy. *Journal of Medical Systems*, 2002; 24(4):235-46

BOOKS and CHAPTERS

1. **Brixner DI, Joish VN, Biskupiak JE**, Shah H. (2006). "Pharmacoeconomic Research in Managed Care" in Managed Care Pharmacy Practice (Robert Navarro). 2nd edition, New York, Aspen Publishers.

ABSTRACTS and POSTERS

2009 Abstracts

1. **Ghate SR, Biskupiak J**, Casciano J, Hagan M, **Brixner DI**. Rate of Bleeding Events and Comorbidities among Atrial Fibrillation Patients Treated With or Without Warfarin. *25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ISPE)*. Rhode Island. (Forthcoming August 16-19, 2009)
2. **Brixner D, McAdam-Marx C, Nelson R**, Aagren M, Bouchard J. Analysis of glycemic control and weight changes in patients treated with analog basal insulin in a real-world setting. *American Diabetes Association, 69th Annual Scientific Meeting*. New Orleans, LA. June 2009 (Published Abstract).
3. Fabunmi R, **McAdam-Marx C, Ye X**, Misurski D, **Brixner D**. Blood Pressure Outcomes after 6 Months of Exenatide Treatment in Patients with Type 2 Diabetes in a Real World Study. *American Diabetes Association, 69th Annual Scientific Meeting*. New Orleans, LA. June 2009
4. **Kim J**, Phatak H, **Biskupiak J**, Wu D, Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice. *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009
5. **Kim J, Asche CV**, Anderson KH, Kahler KH, Kulkarni A, Assessment Of Cardiovascular (CV) Comorbidity In Patients With Overactive Bladder (OAB) Disorder In A Real-World Setting. *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009
6. **McAdam-Marx C, Yu J**, Shankar V, Bouchard J, **Brixner DI**. Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes. *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009
7. **Kim J**. Finite Mixture Regressions in Modeling Prescription Drug Utilization and Prescription Drug Expenditures of Patients with Rheumatoid Arthritis (Ra). *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009
8. **McAdam-Marx C, Brixner DI, X Ye**, Misurski D, Fabunmi R. A1C and Weight Outcomes Following 6 Months of Analog Basal Insulin in Insulin Naïve Patients with Type 2 Diabetes in an Ambulatory Care Setting. *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009
9. **Brixner DI, McAdam-Marx C, X Ye**, Misurski D, Wintle M, Fabunmi R. 18 month A1C and Weight Outcomes of Exenatide Therapy in Patients with Type 2 Diabetes in a Real-World Study. *14th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Orlando, FL. May 2009

10. **Kim J, Asche CV.** Pharmacological Side Effects of Antimuscarinic Drugs on Heart Rate: GEE and Multilevel Approaches. *5th Annual Utah Health Services Research Conference.* (Podium Presentation) Salt Lake City, UT. May 2009
11. **Yu J, Brixner DI, Ghate S,** Gordon K. A Pilot Study of Screening Outcomes in Patients at Risk for Atherosclerosis in the Utah Community Clinics. *5th Annual Utah Health Services Research Conference*(Podium Presentation) Salt Lake City, UT. May 2009
12. **Kim J, Biskupiak JE,** Phatak H, Wu D. Assessment of the Presence of High Risk Cardiovascular Conditions and the Status of Hypertension Management among Elderly Adults in the US Primary Care Practices. *5th Annual Utah Health Services Research Conference.* (Podium Presentation) Salt Lake City, UT. May 2009
13. **Oderda GM, McAdam-Marx C,** Cleveland J, Roland CL. Direct Costs of Opioid Abuse in Medicaid Patients. *AMCP 21st Annual Meeting & Showcase.* Orlando, FL. April 2009
14. **Kim J, Asche CV,** Kahler K, Kulkarni A. Assessment of Cardiovascular (CV) Comorbidity in Patients with Overactive Bladder (OAB) Disorder in a Real-World Setting. *Western Pharmacoeconomics Conference 2009.* Pasadena, California. March 2009
15. **Nelson RE, LaFleur J,** Pickard SG, Nebeker JR. Predictors of Bisphosphonate Treatment in Male United States Veterans. *Western Pharmacoeconomics Conference 2009.* Pasadena, California. March 2009
16. **Kim J, Biskupiak J.** Assessment Of The Status Of Hypertension Management In Newly Diagnosed And Established Hypertension Patients In Primary Care Practice. *Western Pharmacoeconomics Conference 2009.* Pasadena, California. March 2009
17. **Nelson RE, LaFleur J,** Pickard S, Nebeker J. "Predictors of an osteoporosis diagnosis in male United States veterans" [podium presentation]. 2009 Western Pharmacoeconomics Conference. Palo Alto, California. Pasadena, California. March 2009.
18. **McAdam-Marx C, Yu J,** Shankar V, Bouchard J, **Brixner DI.** Daily Average Consumption of Basal Insulin in Patients with Type 2 Diabetes. *Western Pharmacoeconomics Conference 2009.* Pasadena, California. March 2009

2008 Abstracts

1. **Brixner DI,** Malone, D, Watkins J. Advancing the Use of Real World Data in Formulary and Reimbursement Decision Making. *AMCP 2008 Educational Conference.* Kansas City, MO. October 2008
2. **LaFleur J, McAdam-Marx C,** Pickard SG, Nebeker JR. Recognition and treatment of male osteoporosis is low. *ASBMR 30th Annual Meeting,* Montreal, Montreal, Canada, September 2008
3. **Brixner DI, Oderda G, Ye X,** Boye KS, Wintle M, Fabunmi R. Clinical Effectiveness of Exenatide in Patients with Type 2 Diabetes in a Primary Care Electronic Medical Record Database. *American Diabetes Association 68th Scientific Sessions.* San Francisco, CA. June 2008

4. **Nelson RE, Lafleur J, McAdam-Marx C, Brixner DI**, Ward R. Patent extension policies for pediatric indications: an evaluation of the impact within one drug class in one state Medicaid program. *Academy Health 2008 Annual Meeting*. June 2008. Washington, DC.
5. Shafazand S, Yang Y, Mitsi G, **Brixner DI**. Heart Failure Quality of Care: Views from a Nationwide Administrative Claims Database. *American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke*, Baltimore, Maryland, May 2008
6. **Nickman NA**, Haak SW, Harald EA, **Holtorf AP**, Joshi AV, Kim JW, **Brixner DI**. Cost Minimization Analysis of Different Growth Hormone Devices Based on Time-And-Motion Simulations. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
7. **Roper M, Biskupiak J**, Alder S, **Oderda G**. Comparison of Men Age 21 Years and Older with and w/out Erectile Dysfunction on Concomitant Prescription Drug, Comorbid Conditions, Smoking Status and BMI. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
8. **Brixner DI, McAdam-Marx C, Biskupiak J**, Lau HJ, Munger M. Association of Adverse Events of Antihypertensive Therapy by Age in a Physician Practice National EMR Database. *American Heart Association 9th Scientific Quality of Care Cardiovascular Disease and Stroke*, Baltimore, Maryland, May 2008
9. **McAdam-Marx C, Brixner DI**, Field R, Metraux S. Type 2 Diabetes in Youth: 2002 and 2006 Prevalence and Obesity in a Primary Care Setting. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
10. **McAdam-Marx C, Brixner DI, Oberg B**. Estimation of Study Population Size for Effectiveness Outcomes at 6 and 12 months via Electronic Medical Records. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
11. **McAdam-Marx C, Brixner DI, Ye X**, Sung JC, Kahler KH. Evaluation of Resistant Hypertension in a Usual-Care Setting. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
12. **Nelson R, McAdam-Marx C**, Misurski DA, Nielsen LL. Descriptive analysis of body weight and clinical effectiveness measures associated with type 2 diabetes therapies in a primary care electronic medical record database. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
13. **Ghate SR, Said Q**, Huse D, Ben-Joseph R, **Brixner DI**. Projected Cost of Cardiometabolic Risk Factors in Commercially Insured Normal and Overweight US Primary Care Patients. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008

14. **LaFleur J, Ghate SR, Sauer B.** Updating The RxRisk-V: Creating A Crosswalk Between VA And Firstdatabank Therapeutic Categories. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
15. **LaFleur J, Ghate SR, Ye X.** Estimating Sociodemographic Variables In A Pharmacy Dataset: Applying Data From Us Census 2000. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
16. **Ghate SR, LaFleur J, Charland SL, Sauer B.** A Modified Rxrisk-V Comorbidity Index Predicts Adherence With Lipid Lowering Therapy (LLT). *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
17. Hassanein TI, Ye X, Blumentals WA, **Brixner DI.** Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *Digestive Disease Week*, San Diego, California, May, 2008
18. **McAdam-Marx C, Brixner DI, Asche C.** Identifying potential adverse events in an electronic medical record database. *4th Annual Utah Health Services Research Conference*. April 25, 2008. Salt Lake City, UT.
19. Hassanein TI, Ye X, Blumentals WA, **Brixner DI.** Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy*, Phoenix, Arizona, April, 2008
20. **Ghate SR, Doan J, Nelson R, Van Den Bos J, Brixner DI.** Indirect Costs Associated with Patients Treated for Insomnia: An Employer Perspective. *2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy*, Phoenix, Arizona, 2008, April, 2008
21. Hassanein TI, Ye X, Blumentals WA, **Brixner DI.** Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin. *43rd Annual Meeting European Association for the Study of the Liver (EASL)*, Milan, Italy, April, 2008

2007 Abstracts

1. Muszbek N, **Brixner D**, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 1st Latin America Conference, Cartagena, Columbia, 2007
2. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence During the Chronic Phase in Patients with Ulcerative Colitis. *American College of Gastroenterology Annual Scientific Meeting*, Philadelphia, Pennsylvania, 2007
3. **Brixner DI**, **Jackson K**, Sheng X, **Biskupiak J**, Keskinaslan A. Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Conference*, Dublin, Ireland, 2007
4. **Asche CV**, Seal B, **McAdam-Marx C**, Crookston B, Svejda R, Mullins CD. Treatment costs associated with community acquired pneumonia by community level antimicrobial resistance. *ISPOR 10th Annual European Congress*. October 20-23, 2007; Dublin, Ireland.
5. **Asche CV**, **McAdam-Marx C**, Shane-McWhorter L, Sheng X, Plauschinat CA. Association between oral antidiabetic adverse events and outcomes in a real world setting. *ADA 67th Specific Meeting*. 2007 June; Chicago, IL 2126-PO.
6. **McAdam-Marx C**, **Brixner D**, Metrau S, Chan V, PharmD3, Field R. Determinants of race and ethnicity reporting for youth with health data in an electronic medical record database. *University of the Sciences Scholarly Day*. 18 April, 2007. Philadelphia, PA.
7. **LaFleur J**, **Asche CV**, **McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. *3rd Annual Utah Health Services Research Conference*, Friday April 6, 2007, Salt Lake City, UT.
8. **LaFleur J**, **McAdam-Marx C**, **Asche CV**, Alder S, Sheng X, **Brixner D**, Silverman S. "Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting" [poster]. *The American Society of Bone and Mineral Research 29th Annual Meeting*. Honolulu, Hawaii. September 2007.
9. **LaFleur J**, **McAdam-Marx C**, **Asche CV**, **Alder S**, Sheng X, **Brixner D**, Silverman S. "The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk factors in a primary-care setting" [poster and abstract]. *7th International Symposium on Osteoporosis: Translating Research into Clinical Practice*. Washington, D.C. April 2007. *Osteoporosis International* 2007;18(Supplement 2):S210.

10. **LaFleur J**, McBeth C, Steinvoort C, Oderda L, Paul M, Gunning K, **Oderda G**. "Identification and categorization of drug-related problems among Medicaid patients: Variability between pharmacist reviewers". *American College of Clinical Pharmacy 2007 Spring Practice and Research Forum*. Memphis, Tennessee. April 2007. *Pharmacotherapy* 2007;27(4):31.
11. Atherton A, **LaFleur J**, Mayeda B, Oderda L, **Oderda GM**. "Comparison of drug-related problems in nursing home residents versus non-nursing home Medicaid patients". *American College of Clinical Pharmacy 2007 Spring Practice and Research Forum*. Memphis, Tennessee. April 2007.
12. **Holtorf A-P**, **LaFleur J**, Servatius D, Jeffries B, **Brixner DI**. "Prescription drug use by women and men in Utah Medicaid". *Utah Health Services Research Meets Public Health Informatics*. Salt Lake City, Utah. April 2007.
13. **Holtorf A-P**, **LaFleur J**, Servatius D, Jeffries B, McBeth C, **Brixner DI**. "Statin treatment of diabetic patients in Utah Medicaid". *Utah Health Services Research Meets Public Health Informatics*. Salt Lake City, Utah. April 2007.
14. **Nickman NA**, Haak SW, **Holtorf AP**, Joshi AV, **Brixner DI**. Time-and-motion evaluation of different growth hormone formulations. *ISPOR 10th Annual European Congress*, Dublin, Ireland: October 2007.
15. **Biskupiak J**, **Brixner DI**, Keskinaslan A. Effectiveness of Multiple-Mechanism Antihypertensive Medication: Valsartan-Amlodipine-HCTZ Triple-Therapy in Primary Care. *ISPOR 10th Annual European Congress*, Dublin, Ireland, October 2007
16. **Biskupiak J**, **Brixner DI**, Munger M, Keskinaslan A. Effectiveness of Amlodipine Valsartan Combination Therapy in Primary Care. *European Society of Hypertension, 17th European Meeting on Hypertension*, Milan, Italy, June 2007.
17. **Jackson K**, **Brixner DI**, **Oderda G**, **Oberg B**, Sheng X, Keskinaslan A. Compliance and Economic Outcomes with Valsartan and HCTZ Combination Therapy for Hypertensive Patients. *American Society of Hypertension*, June 2007.
18. Kane S, Magowan S, Accortt N, **Brixner DI**. Predictors of 5-ASA Prescription Persistence in Patients with Ulcerative Colitis. *Digestive Disease Week 2007*, Washington, D.C., May 2007.
19. **Brixner DI**, Magowan S, Accortt N. Prescription Refill Behavior for Nifedipine Therapy is Significantly Dependent on Medication Cost. *8th American Heart Association Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke*, Washington, D.C., May 2007.
20. **Brixner DI**, **Ghate SR**, **McAdam-Marx C**, Ben-JosephR, **Said Q**. Correlation of Weight to Cardiometabolic Risk as Identified by ICD-9 Diagnosis Codes and Prescriptions in Primary Care. *International Society for Pharmacoeconomics and Outcomes Research*, Arlington, Virginia, May 2007.
21. **Brixner DI**. Contraceptive and non-contraceptive benefits of a Levonorgestrel-releasing intrauterine in a vertically integrated HMO. *International Society for Pharmacoeconomics and Outcomes Research*, Arlington, Virginia, May 2007.

22. **Brixner DI**, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. *Academy of Managed Care Pharmacy 19th Annual Meeting & Showcase*, San Diego, California, April 2007.
23. **Brixner DI, Said Q, Oderda G, Kirkness C**. Assessment of the clinical risk factors for cardiometabolic risk in a national primary care electronic medical record (EMR) database. *Academy of Managed Care Pharmacy 19th Annual Meeting & Showcase*, San Diego, California, April 2007.
24. **Nickman NA**, Haak SW, **Holtorf AP**, Joshi AV, **Brixner DI**. Time-and-motion evaluation of different growth hormone formulations. *ISPOR 10th Annual European Congress*. October 2007; Dublin, Ireland.
25. **Asche CV**, Machado M, Caro J. "ISPOR Digest of International Databases for Pharmacoeconomics and Outcomes Research" *1st Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Cartagena, Columbia, 2007
26. **Asche CV**, Young D, **Brixner DI**, Phillips A. "Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database" *American College of Clinical Pharmacy (ACCP) 2007 Spring Practice and Research Forum*, Memphis, TN, April 21 – 25, 2007
27. **Asche CV**, Mucha L, Lenhart G, Seal B. "Incremental Costs Associated Antibiotics Prescribed for Community Acquired Pneumonia Episodes" *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007.
28. Mucha L, Seal B, Lenhart G, **Asche CV**. "Direct and Incremental Costs of Acute Respiratory Infections" *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007
29. Seal B, Mucha L, Lenhart G, **Asche CV**. "Incremental Costs Associated with Antibiotics Prescribed for Acute Otitis Media" *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007
30. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *Utah Health Services Research Conference*, VA Salt Lake City Health Care System, Salt Lake City, UT, 2007
31. **Asche CV**, Oderda LH, Pepper GA. "The Economic Impact of Treatment of Falls-Related Injuries from a U.S. Employers Perspective" *Center on Aging Research Retreat*, Salt Lake City, UT, 2007
32. **Asche CV, McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. "Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting" *American Diabetes Association (ADA)*, Chicago, IL, 2007.

33. **Asche CV**, Cummings G. "ISPOR Digest of international databases for pharmacoconomics and outcomes research" *10th Annual European Meeting of the International Society of Pharmacoconomics and Outcomes Research (ISPOR)*, Dublin, Ireland, 2007
34. **Oderda G**, Lieberman M, **Asche CV**, **Brixner DI**. "Use of electronic medical record (EMR) data in outcomes research" *10th Annual European Meeting of the International Society of Pharmacoconomics and Outcomes Research (ISPOR)*, Dublin, Ireland, 2007
35. **Ghate SR**, **Kirkness C**, **Biskupiak J**. Assessment of Comorbidities and Prevalence in Patients with GERD using the GE EMR Database. Submitted and presented at the Second Western Pharmacoconomics Conference, Salt Lake City, UT 2007
36. **Asche CV**, **Brixner DI**, L'Italien GJ. "Pharmaco-economic Research in Latin America: Gathering the Data for Dossier Requirements" *1st Annual Latin American Meeting of the International Society of Pharmacoconomics and Outcomes Research (ISPOR)*, Cartagena, Columbia, 2007

2006 Abstracts

1. **Asche CV**, **Young D**, **Brixner DI**, Phillips A. Assessment of asthma/chronic obstruction pulmonary disease (COPD) outcomes via databases. *72nd Annual international, assembly of the American College of Chest Physicians (ACCP). Chest*. October 21-26, 2006. SLC, UT.
2. **Brixner DI**, **Joish VM**, **McAdam-Marx C**, Arondekar B, Hoblyuk R. Evaluation of Persistence and Outcomes in Patients on SU Combination Therapy with TZDs or Metformin. In *AMCP 18th Annual Meeting*. 2006 April. Seattle Washington.
3. **Brixner DI**, **Nickman N**, **Oderda GM**. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. *International Society of Pharmacoconomics and Outcomes Research (ISPOR) Asian Congress* May 2006, Shanghai, China.
4. McGarry LJ, Iskander R, Seal B, **Asche CV**, Thompson D, Weinstein MC. Cost-effectiveness of telithromycin in the treatment of community acquired pneumonia. *11th Annual International Meeting of the International Society of Pharmacoconomics and Outcomes Research*. Philadelphia, PA 2006
5. Haak S, **Nickman N**, Rusho W, Beck S, **LaFleur J**, **Brixner D**. Joint Professional Analysis of a Novel Dosage form in the Intensive Care (ICU) Setting. *American Association of Critinical Care Nurses*; May 2006, Anaheim, California.
6. **LaFleur J**, **Oderda GM**, Lyon JL, White G. The Case of Lipid-Lowering Therapy: A Comparison of Adherence Measurement Methodologies Using Administrative Claims Data. *11th Annual International Meeting of the International Society of Pharmacoconomics and Outcomes Research*. Philadelphia, PA. May 2006

7. **McAdam-Marx C, Joish VN, Brixner DI**, Hoblyuk R. A Comparison of Adherence and Cost of Sulfonylureas in Combination with TZDs or Metformin. *ADA 66th Specific Meeting*. 2006 June; Washington D.C.
8. **Oderda GM, Said Q**, Evans RS, Stoddard GJ, Rublee D, Lloyd J, Samore MH. Opioid-related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay. *25th Annual Scientific Meeting. American Pain Society*. May 2006. San Antonio, Texas.
9. **LaFleur J, Asche CV, McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. *American Society of Health-System Pharmacists. 41st Mid-Year Meeting*. December 3-7, 2006 Anaheim, CA.
10. **Asche CV, McAdam-Marx C**, Share-McWhorter L, Plauschinat CA. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *American Society of Health-System Pharmacists. 41st Mid-Year Meeting*. December 3-7, 2006 Anaheim, CA.
11. **Brixner DI, McAdam-Marx C**, Gallwitz W, **Roper M, Asche CV**. Value of Reducing Vertebral Fractures in Women with Post-Menopausal Osteoporosis with Multiple Clinical Risk Factors for Fracture Based on the TOP Study. *American Society of Health-System Pharmacists 41st Midyear Clinical Meeting*, Anaheim, California, December 2006.
12. **Brixner DI, Ghatte SR, McAdam-Marx C**, Maio V. Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *9th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research*, 2006, Copenhagen Denmark
13. **Asche CV, Brixner DI**, Conoscenti CS, Young D, Shah H, Phillips AL. Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database, *American College of Chest Physicians Meeting*, Salt Lake City, Utah, October 2006.

2005 Abstracts

1. **Asche CV, Stockdale W**, Pepper G, Gallagher EM. The Economic Impact of Treatment of Falls-Related Injuries. *Canadian Association of Population Therapeutics*; Vancouver, British Columbia, 2005
2. **Asche CV, Oderda G**. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. *College of Pharmacy Research Symposium*; University of Utah, Salt Lake City, Utah, 2005
3. **Asche CV, Stockdale W**, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries from a U.S. Employers Perspective. *International Association of Gerontology*, Rio de Janeiro, Brazil, 2005

4. **Biskupiak JE, Brixner DI, Oderda GM**, Howard K. Gastrointestinal Complications of over-the-counter non-steroidal anti-inflammatory drugs. *ACG 70th Annual Scientific Meeting*; October Honolulu, HI, 2005
5. **Brixner DI, Nickman N, Oderda GM**. Documentation of pharmacy cost in the preparation of chemotherapy infusions in academic and community based oncology practices. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR), 8th European Congress*, October Florence, Italy, 2005
6. **Brixner DI, Said Q**, Newcomer J, Tuomari V, **Oderda GM, Stockdale WA**, L'Italien GJ. Real world usage of weight gain drugs in patients on second-generation anti-psychotics. *American Psychiatric Association*. Atlanta, GA, 2005
7. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. *European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis*, Rome Italy, 2005
8. **Brixner DI, Said Q**, Newcomer J, Tuomari V, **Oderda GM, Stockdale W**, L'Italian. Diagnostic Coding for Patients on Second Generation Antipsychotics in Real World. *American Psychiatric Association*; Atlanta, GA, 2005
9. **Brixner DI, Ho MJ**, Sauer BC, **Stockdale WA**. Development of an integrated diabetes database across community clinics and hospitals. *International Society of Pharmacoeconomics and Outcomes Research*, Washington, D.C., 2005.
10. **Brixner DI**, Blonde L, **Said Q**, Tuomari V, **Oderda GM**, Corey-Lisle PK, L'Italian GJ. Real World Impact of Second Generation Antipsychotics on Weight Gain. *American Diabetes Association*, San Diego, CA, 2005
11. Carter O, MacCarter D, Mannebach S, **Biskupiak J**, Stoddard G, Giblert EM, Munger MA. D-Ribose improves peak exercise capacity and ventilatory efficiency in heart failure patients. *JACC* 2005; 45(Suppl A):185A.
12. Haak S, **Nickman NA**. Nursing and Pharmacy Collaboration in Use of Simulation for Time and Motion Study. *Nursing Learning Resource Center Conference*, Villanova University, Philadelphia, PA. 2005
13. **Joish VN**, Brady E, **Stockdale WA**, Dirani R, **Brixner DI**. Identification and diagnosis of COPD in a primary care setting. *International Conference American Thoracic Society*; San Diego, CA. 2005
14. **Joish VN, Brixner DI, LaFleur J, Kirkness C**. Pharmacoeconomic analysis of ARB therapy in patients with mild-to-moderate hypertension. *Academy of Managed Care Pharmacy 2005 Educational Conference*; Nashville, TN.
15. **Joish VN, Stockdale WA**, Brady E, Dirani R, **Brixner DI**. An assessment of diagnosis and treatment of COPD in primary care via an electronic medical record database. *International Society of Pharmacoeconomics and Outcomes Research*; 2005

16. **LaFleur J**, Thompson CJ, **Joish VN**, Charland S, **Oderda GM**, **Brixner DI**. Adherence and persistence with lipid-lowering pharmacotherapy: Effects of the covariates copay and disease severity on probabilities of being categorized as compliant. *Pharmacotherapy Outcomes Research Center*; Kos Pharmaceuticals, Inc.
17. **LaFleur J**, Fowler MA, McBeth C, Oderda L, Gunning K, Steinvooort C, **Stockdale W**, **Oderda GM**. Prevalence of drug-related problems among Medicaid high utilizers as identified by clinically-trained pharmacist reviewers *American College of Clinical Pharmacy 2005 Spring Practice and Research Forum and Updates in Therapeutics*. Myrtle Beach, South Carolina, 2005
18. Lipman AG, **Jackson KC**, **Stockdale W**, **Oderda GM**. The Treatment Outcomes of Pain Survey (TOPS): A Validated Health Related Quality of Life (HRQoL) Outcomes Instrument for Research and Practice. *11th World Congress on Pain. International Association for the Study of Pain*. Sydney, Australia, 2005
19. Maio V, Yuen E, **Brixner D**, **Oderda G**, **Asche CV**, Smith K.D, Morgan S. Multi-national assessment of outcomes via retrospective databases, Healthcare Policy Development Issues, Contributed Workshops, *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 8th European Congress*, October, Florence, Italy, 2005
20. **Oderda G**, **Asche CV**, **Stockdale W**, Spalding J. (2005). Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. *13th Annual Congress on Women's Health Congress*; Hilton Head Island, SC.
21. Roland C, **Biskupiak J**. Number of intrathecal pumps being used for chronic intractable pain. *American Pain Society 24th Annual Scientific Meeting*; Boston, Massachusetts, 2005
22. **Said Q**, **Ho MJ**, Beckwith MC, **Brixner DI**. A Pharmacoeconomic comparison of Oral Fluoroquinolones for Complicated Urinary Tract Infections. *Academy of Managed Care Educational Conference*; Denver, CO, 2005; *Academy of Managed Care Educational Conference*, Nashville, Tennessee, 2005.
23. **Brixner DI**, Borisov NN, Burge RT, Steinbuch M. Cost Analysis of Osteoporosis Treatments: A Managed Care Perspective. *National Osteoporosis Foundation, Sixth International Symposium on Osteoporosis*, Washington, D.C., 2005
24. **LaFleur J**, Thompson C, **Ho MJ**, **Stockdale WA**, Charland S, **Oderda GM**, **Brixner DI**. Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population.
25. **Brixner DI**, **Ho MJ**, Sauer BC, **Stockdale WA**. Real world usage of weight gain drugs in patients on second-generation antipsychotics. *American Diabetes Association*, 2005.

2004 Abstracts

1. **Asche CV, Stockdale W**, Pepper G, Gallagher EM. The economic impact of treatment of falls-related injuries. *Canadian Association of Population Therapeutics*, 2004
2. **Brixner DI**, Tabb K. Overview of databases used in managed care research. *9th Annual Meeting, International Society of Pharmacoeconomics and Outcomes Research*; Washington, DC, 2004
3. **Brixner D, Asche CV**, Chang J, Stewart J, Paladino JA. Economic value of telithromycin vs clarithromycin in the treatment of community-acquired pneumonia. *39th American Society of Health-System Pharmacists (ASHP), Midyear Clinical Meeting*; Orlando, Florida, 2004
4. **Brixner DI**, Cannon HE, **Oderda GM, Stockdale WA, Joish VN**, Hanson D. Impact of varying copays on patient prescribing behavior in a managed care organization: focus on hypertension. *Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase*; San Francisco, CA, 2004
5. Christensen RL, **LaFleur J, Ho MJ, Joish VN, Brixner DI**. Which HMG-CoA reductase inhibitor for hyperlipidemia: a cost-effectiveness analysis based on the STELLAR trial. *Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase*; San Francisco, CA, 2004
6. **Ho MJ, LaFleur J, Brixner D**. What is the Cost for Atypical Antipsychotics for Schizophrenia: Efficacy versus Effective Doses [poster]. *Academy of Managed Care Pharmacy 2004 Educational Conference*; Baltimore, Maryland, 2004.
7. **Ho MJ, LaFleur J, Brixner DI**. Which atypical antipsychotics for schizophrenia: cost-efficacy versus cost-effectiveness analyses. *Academy of Managed Care Pharmacy*; Baltimore, MD, 2004
8. **Ho MJ, Joish VN, LaFleur J**, Christensen RL, **Brixner DI**. Which oral triptan for migraine: a cost-efficacy analysis from a managed care perspective. *Academy of Managed Care Pharmacy 16th Annual Meeting and Showcase*; San Francisco, CA, 2004
9. **Ho MJ, Joish VN, Stockdale W, Oderda GM**, Alder S, White G. Does recommended self-blood glucose monitoring impact overall healthcare resource use. *American Society of Health-Systems Pharmacists, 39th Midyear Clinical Meeting*, Orlando, Florida, 2004
10. **Joish VN**, Malone DC, Wendel C, Mohler MJ. Development of a diabetes resource consumption index (DRCI): a risk adjustment tool for predicting healthcare resource use and costs. *Value in Health*. 2004
11. **Joish VN**, Donaldson G, **Stockdale WA, Oderda GM, Brixner DI**, Sasane R, Joshua-Gotlib S, Crawley JA. Economic burden of GERD and PUD in an employed population. *9th Annual Meeting International Society of Pharmacoeconomics and Outcomes Research*; Arlington, VA, 2004

12. **LaFleur J**, Beckwith C, Fowler M, Tyler L, **Brixner D**. A Pharmacoeconomic Comparison of Oral Third-Generation Cephalosporins for Acute Otitis Media [poster]. American Society of Health-System Pharmacy *39th Midyear Clinical Meeting*. Orlando, Florida, 2004
13. **LaFleur J**, Thompson C, **Ho MJ**, **Stockdale WA**, Charland S, **Oderda GM**, **Brixner DI**. Adherence, persistence, and cost of lipid-lowering pharmacotherapy: ER-niacin/statin combination therapy within a single dosage-form versus two separate dosage forms in a managed care population. *Academy of Managed Care Pharmacy*; Baltimore, MD, 2004.
14. **LaFleur J**, **Oderda G**, **Stockdale W**, Gunning K, Orlando P, Steinvort C, Tyler L. Impact of Pharmacist Reviews on Prescribing Behavior. *ACCP Spring Meeting*; Paris, France, 2004
15. **Oderda GM**, **LaFleur J**, Gunning K, **Stockdale W**, Orlando P, Steinvort C. Impact of Structured Patient Reviews of High Prescription Utilizers on the Cost of Care. *American College of Clinical Pharmacy (ACCP) and European Society of Clinical Pharmacy Joint, Spring Meeting*; Paris, France, 2004
16. **Oderda GM**, **LaFleur J**, Gunning K, **Stockdale W**, Orlando P, Steinvort C. Reducing Drug Costs via a Structured Review of High Utilizers in the Utah Medicaid Program. *ACCP Spring Meeting*; Paris, France; April 2004.
17. Oderda L, Young E, **Oderda G**. Graduate Employability: A Longitudinal Comparison of Preceptors' Opinions about Hiring Clerkship Students After Multiple Professional Experiences: 2000-2003. *American Association of Colleges of Pharmacy Meeting*; Salt Lake City, Utah, 2004
18. **Stockdale WA**, **Brixner DI**. Comorbidity influence index. *9th Annual Meeting International Society of Pharmacoeconomics and Outcomes Research*; Arlington, VA, 2004

2003 Abstracts

1. **Brixner DI**, Cannon HE, **Oderda GM**, **Biskupiak JE**, **Stockdale WA**, **Joish VN**, Hanson D. Impact of varying copays on patient prescribing behavior in a managed care organization; preliminary results. *Academy of Managed Care Pharmacy 15th Annual Meeting*; Minneapolis, MN, 2003
2. **Brixner DI**, Tabb K. Overview of database used in managed care research. *Academy of Managed Care Pharmacy 15th Annual Meeting*; Minneapolis, MN, 2003
3. **Brixner DI**, Avey SG, Malone D. Practical decision analysis for the decision maker. *International Society For Pharmacoeconomics and Outcomes Research Spring Meeting*; Arlington, VA, 2003
4. **Oderda GM**, Gunning KM, **LaFleur J**, **Stockdale WA**, Tyler LS, Parke D, **Brixner DI**. Reviews of Utah Medicaid high utilizers to control drug costs. *International Society For Pharmacoeconomics and Outcomes Research Spring Meeting*; Arlington, VA, 2003

5. Oderda LH, **Stockdale WA**, **Oderda GM**, Donaldson G, Ashburn M, **Brixner DI**, Lipman AG. Age and gender-stratified differences in quality of life in elderly chronic pain patients. *International Society For Pharmacoeconomics and Outcomes Research Spring Meeting*; Arlington, VA, 2003
6. Gunning KM, **Oderda GM**, **Stockdale WA**, **LaFleur J**, Orlando PL, Steinvort C, Dang K, Tyler LS, **Brixner DI**. Controlling Utah Medicaid drug spending through a regimen review program. *American College of Clinical Pharmacy*, Orlando, Florida, 2003.
7. Sahai A, Skrepnek G, **Joish VN**. On improved confidence-interval estimation of cost-effectiveness ratios. International Conference on Statistics, Combinatorics and Related Areas, *10th Conference of the Forum for Interdisciplinary Mathematics*; Portland, ME, 2003

2002 Abstracts

1. **Brixner DI**, Todd W. Compliance and persistency programs as a component of disease management programs in managed care. *Academy of Managed Care Pharmacy 14th Annual Meeting*; Salt Lake City, UT, 2002.
2. **Oderda GM**, Lipman AG, Ashburn MA, **Stockdale W**. Use of the Tops as A Pain-Specific HRQOL Instrument. *ISPOR Fifth European Congress*; Rotterdam, Netherlands, 2002

INVITED PRESENTATIONS

2009 Presentations

1. **Nelson RE, LaFleur J**, Pickard S, Nebeker J. “Predictors of an osteoporosis diagnosis in male United States veterans” [podium presentation]. 2009 *Western Pharmacoeconomics Conference*. Palo Alto, California. Pasadena, California. March 2009.
2. **LaFleur J, Nelson R**, Pickard S, Nebeker J. “Gathering evidence for clinical decision support in male osteoporosis in veterans” [podium presentation]. *2009 University of Utah Center on Aging Research Retreat*. Salt Lake City, Utah. March 2009
3. **Oderda GM**. Naresuan University. Pharmacoeconomics. Phitsanulok, Thailand. March 2009
4. **LaFleur J, Nelson R, McAdam-Marx C**, Pickard S, Nebeker J. “Electronic clinical and administrative data can be used to predict patients at risk of fragility fracture” [podium presentation]. *2009 HSR&D (Health Services Research and Development) National Meeting*. Baltimore, Maryland. February 2009.
5. **Brixner DI**. Guidelines for Research Using “Real World Data”. Enhancing the Rigor and Utility of Medication Use Research A Consensus Development Conference. Rockville, MD. January 2009 *Co-sponsored by AACP, PPRA, ISPOR and USP*

2008 Presentations

1. **Brixner, DI, McAdam-Marx, C, Ye, XY, Boye, K, Fabunmi, R, Schroeder, B**. Real World Six Month Outcomes of Patients Initiating Exenatide in a Primary Care Electronic Medical Record Database. *13th Annual International Meeting International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May, 2008
2. **Asche CV, Jacobs P, Yim R**. Economic databases for pharmacoeconomic evaluations in Canada: Overview and use. *13th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Toronto, Canada, May 2008
3. **Ghate SR, Said Q, Rosenblatt LC, Kim E, Pikalov A, Brixner DI**. Real World Association between Antipsychotic Treatment and Weight Gain in an Adolescent Population. *International Society of Pharmacoeconomics and Outcomes Research 13th Annual International Meeting (ISPOR)*, Toronto Canada, May 2008

2007 Presentations

1. **Brixner DI, Ghate SR, McAdam-Marx C, Maio V.** Analysis of Prescribing Patterns of Antihypertensive Agents (AA) Before and After Publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 1st Latin America Conference*, Cartagena, Columbia, 2007
2. **Brixner DI, Jackson K, Sheng X, Biskupiak J, Keskinaslan A.** Compliance with Multiple Combination Antihypertensive Pharmacotherapy in a Large US Database. *ISPOR 10th Annual European Congress*, Dublin, Ireland, 2007
3. **Said Q, Ghate SR, McAdam-Marx C, Brixner DI.** Correlation of weight to cardiometabolic risk as identified by ICD-9 diagnosis codes and prescriptions in primary care. *ISPOR 12th Annual International Meeting*, Arlington, VA
4. **LaFleur J, McAdam-Marx C, Asche CV, Alder S, Sheng X, Brixner DI, Silverman S.** The risk of clinical vertebral fracture for postmenopausal patients with specific combinations of fracture risk Factors in a primary-care setting. [Poster] *National Osteoporosis Foundation, 7th International Symposium on Osteoporosis: Translating Research into Clinical Practice*, Washington, DC
5. **Brixner DI.** The Differences Between RCTs and “Real World” Studies. Real World Data and the Formulary Decision Process: *Bridging the Gap*, San Diego, CA.
6. **Said Q, Gutterman E, Kim M, L’Italien G, Chi-Chang C, Whitehead R, Brixner DI.** The Association Between Antipsychotic Treatment and Unintentional Injury in Patients Diagnosed with Psychiatric Disorder. *2007 International Congress on Schizophrenia Research*, Colorado Springs, CO / *American Psychiatric Association Annual Meeting*, San Diego, CA.
7. **McAdam-Marx C, Brixner DI, Metrau S, Chan V, Field R.** Determinants of Race and Ethnicity Reporting for Youth with Health Data in an Electronic Medical Record Database. *Fifth Annual University of Sciences in Philadelphia Scholarly Day*, Philadelphia, PA.
8. **Brixner DI, Magowan S, Accortt N.** Evaluation of Prescription Refill Patterns Based on Daily Dosing Regimen and Pill Load for Calcium Channel Blockers. *Academy of Managed Care Pharmacy 19th Annual Meeting and Showcase*, San Diego, CA.
9. **Brixner DI, Oderda G, Kirkness C, Said Q.** Assessment of Cardiometabolic Risk in a National Primary Care Electronic Medical Database (EMR). *Academy of Managed Care Pharmacy 19th Annual Meeting and Showcase*, San Diego, CA.
10. **Brixner DI.** The Prevalence and Burden of Migraine and Its Impact on Managed Care. *Academy of Managed Care Pharmacy 19th Annual Meeting and Showcase*, San Diego, CA.
11. **Asche CV, Young D, Brixner DI, Phillips A.** Assessment of Physician Prescribing for Primary Care Patients with Chronic Obstructive Pulmonary Disease (COPD) in a National Electronic Medical Record (EMR) Research Database. *American College of Clinical Pharmacy (ACCP) 2007 Spring Practice and Research Forum*, Memphis, TN.

12. **Asche CV**, Machado M, Caro J. ISPOR Digest of International Databases for Pharmacoeconomics and Outcomes Research. *1st Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Cartagena, Columbia, 2007
13. **Asche CV**, Cummings G. ISPOR Digest of international databases for pharmacoeconomics and outcomes research. *10th Annual European Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Dublin, Ireland, 2007.
14. **Oderda G**, Lieberman M, **Asche CV**, **Brixner DI**. Use of electronic medical record (EMR) data in outcomes research. *10th Annual European Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Dublin, Ireland, 2007.
15. **Asche CV**, Seal B, **McAdam-Marx C**, Crookston B, Svejda R, Mullins CD. Treatment costs associated with community acquired pneumonia by community level of antimicrobial resistance. *10th Annual European Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Dublin, Ireland, 2007.
16. **LaFleur J**, **McAdam-Marx C**, **Asche CV**, Alder S, Sheng X, **Brixner DI**, Silverman S. Clinical risk factors for fracture are additive in postmenopausal women who are at risk for fracture in a primary care setting. *American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting*, Honolulu, Hawaii, 2007.
17. **Asche CV**, **Brixner DI**, L'Italien GJ. Pharmacoeconomic Research in Latin America: Gathering the Data for Dossier Requirements. *1st Annual Latin American Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Cartagena, Columbia, 2007.
18. **Asche CV**, **McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Adverse Events and Oral Antidiabetic Outcomes in a Real World Setting. *American Diabetes Association (ADA)*, Chicago, IL, 2007.
19. **Asche CV**, Oderda LH, Pepper GA. The Economic Impact of Treatment of Falls-Related Injuries from a U.S. Employers Perspective. *Center on Aging Research Retreat*, Salt Lake City, UT, 2007
20. **LaFleur J**, **Asche CV**, **McAdam-Marx C**, Alder S, Sheng X. Postmenopausal osteoporosis fracture occurrence and fracture rates by age in a primary-care setting. *Utah Health Services Research Conference*, VA Salt Lake City Health Care System, Salt Lake City, UT, 2007
21. **Asche CV**, **McAdam-Marx C**, Shane-McWhorter L, Plauschinat C. Evaluation of diabetes treatment patterns and adverse events in a usual care setting. *Utah Health Services Research Conference*, VA Salt Lake City Health Care System, Salt Lake City, UT, 2007
22. Seal B, Mucha L, Lenhart G, **Asche CV**. Incremental Costs Associated with Antibiotics Prescribed for Acute Otitis Media. *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007

23. Mucha L, Seal B, Lenhart G, **Asche CV**. Direct and Incremental Costs of Acute Respiratory Infections. *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007
24. **LaFleur J, McAdam-Marx C, Asche CV**, Alder S, Sheng X, **Brixner DI**, Silverman S. The Risk of Clinical Vertebral Fracture for Postmenopausal Patients with Specific Combinations of Fracture Risk Factors in a Primary-Care Setting. *National Osteoporosis Foundation (NOF)*, Washington, DC, 2007
25. **Said Q**, Rosenblatt LC, **Ghate SR**, Whitehead R, **Brixner DI**. Real World Impact of Second Generation Antipsychotics on Weight Gain in an Adolescent Population. *59th Institute on Psychiatric Services*, New Orleans, LA, October 11-14, 2007
26. **Asche CV**, Mucha L, Lenhart G, Seal B. Incremental Costs Associated Antibiotics Prescribed for Community Acquired Pneumonia Episodes. *12th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR)*, Arlington, VA, 2007

2006 Presentations

1. **Asche CV**. Overview of Data used in Outcomes Research. Pharmaceutical Market Research Summit. Leverage Pre and Post Launch Market Research Strategies to Improve Initial Product Positioning and Ongoing Strategic Decision Making. *King of Prussia, PA*, 2006
2. **Asche CV**. Improving Outcomes in the Treatment of Lower Respiratory Tract Infections. Independence of Washington State Pharmacy Association Continuing Education Seminars. *Washington State Pharmacy Association (WSPA) Mid-Year Meeting*. Renton, Washington, 2006
3. **Brixner DI** (presenter), **Joish VN, McAdam-Marx C**, Arondekar B, Hoblyuk R. Evaluation of Persistency and Outcomes in Patients on SU Combination Therapy with TZD's or Metformin. *2nd Annual Health Services Research Conference*. Salt Lake City, UT, 2006
4. **Brixner DI**. Pharmacoeconomics of COPD Management. *American Society of Hospital Pharmacists Mid-year Meeting*, Anaheim, CA, 2006
5. **Brixner DI**. Real World Data in Healthcare Decision Making. *European Science Foundation Conference on the Global Health Economy*, Kiel, Germany, 2006
6. **Brixner DI**. Assessment of Cardiometabolic Risk in a Primary Care Electronic Medical Database. *Academy of Managed Care Pharmacy Meeting*, Seattle, WA, 2006
7. **Brixner DI**. Developing and Implementing Pharmacy Policy for Insomnia Therapies within Managed Care Plans. *Academy of Managed Care Pharmacy Meeting*, Seattle, WA, 2006

2005 Presentations

1. **Asche CV.** Prospective Economic Evaluations in Clinical Trials and Examples, *First Western Pharmacoeconomics Conference*; Salt Lake City, Utah, 2005
2. **Asche CV.** Overview of Data used in Outcomes Research. *Strategic Research Institute Conference Patient Level Data for the Pharmaceutical Industry*; Washington, DC, 2005
3. **Brixner DI.** Assessment of the Prevalence and Costs of Osteoporosis Treatment Options in a Real World Setting. *AMCP Symposium*; Nashville, TN, 2005
4. **Brixner DI.** The Case Against Excessive Cost Sharing for Biologics. *AMCP Symposium*; Nashville, TN, 2005
5. **Brixner DI.** Electronic Medical Records in Outcomes Research: The New Frontier. *Jefferson Medical College*; Philadelphia, PA, 2005
6. **Brixner DI.** Improving Outcomes in the Treatment of Lower Respiratory Tract Infections AMCP Framework on Quality Drug Therapy. *AMCP Annual Meeting*; Denver, CO, 2005
7. **Brixner DI.** Managing Your Osteoporosis Formulary to Maximize Bone Strength and Minimize Fracture. *AMCP Annual Meeting*; Denver, CO, 2005
8. **Joish VN.** Risk-adjustment in Outcomes Research: The Case of Diabetes Severity Index. Guest Lecture at the *Ohio State University College of Pharmacy*; Columbus, OH, 2005
9. **Joish VN.** Application of Pharmacoeconomics in the Western World. Guest lecture to post-graduate students at Principal K.M. *Kundnani College of Pharmacy*; Mumbai, India, 2005
10. **Joish VN.** Cost-effectiveness Analysis and Methodological Issues in Pharmacoeconomics Research. 3 day workshop at the India Gandhi Government Medical College, Nagpur, India. Workshop for members of *Indian Clinical Epidemiologists Network (INDIACLEN)*, 2005
11. **Brixner DI, Corey-Lisle P, Oberg B, Tuomari V, Biskupiak JE.** Complexity of Depression Treatments: Healthcare Utilization and Costs. *APA Annual Meeting*, Toronto, Canada, 2005

2004 Presentations

1. **Brixner DI, Jorgenson JA.** Relationship Between Health Systems and Colleges of Pharmacy - AACP-Sponsored Program at the *ASHP Midyear Clinical Meeting*. 2004
2. **Brixner DI.** Managing the Continuum of Treatment: Modeling the Economic Impact of Treating Diabetes. Symposium in conjunction with the *Academy of Managed Care Pharmacy*. 2004
3. **Joish VN.** Introduction to Pharmacoeconomics and Health Outcomes Research. Seminar of pharmaceutical company sales staff at Principal K.M. *Kundnani College of Pharmacy*; Mumbai, India, 2004

2003 Presentations

1. **Brixner DI.** Patient Management in Irritable Bowel Syndrome. *American Society of Health System Pharmacists Midyear Meeting.* 2003
2. **Brixner DI.** The Management of COPD in Managed Care Systems. Pre-Meeting Symposium to the *Academy of Managed Care Pharmacy.* 2003
3. **Brixner DI.** The Economics of Insomnia. Pre-Meeting Symposium to the *Academy of Managed Care Pharmacy.* 2003
4. **Brixner DI.** Evidenced Based Treatment Approaches to Irritable Bowel Syndrome. Pre-Meeting Symposium to the *Academy of Managed Care Pharmacy.* 2003
5. **Brixner DI.** Utilization of the AMCP Format in Medicaid, Medicaid & Medicare, the Changing Landscape. 2003

HOSTED CONFERENCES

1. **First Western Pharmacoeconomics Conference**
Salt Lake City, UT
2005
2. **Second Western Pharmacoeconomics Conference**
Salt Lake City, UT
2007

Pharmacotherapy Outcomes Research Center

421 Wakara Way, Suite 208
Salt Lake City, UT 84108
Phone: (801) 587-9639
Fax: (801) 587-7923
porc@pharm.utah.edu

www.pharmacy.utah.edu/pharmacotherapy/porc/

Last Update: August 2009

